Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05024175 · ClinicalTrials.gov registry record

Long-term Follow-up of Subjects Treated With CAR T Cells

A clinical trial of Adult and CAR-T, sponsored by Marcela V. Maus, M.D.,Ph.D..

Recruiting
Registry status
45
Enrollment target
1
Study location

NCT05024175: Recruiting study of Adult and CAR-T, sponsored by Marcela V. Maus, M.D.,Ph.D..

NCT05024175 is a study of Adult and CAR-T that is actively recruiting participants, run by Marcela V. Maus, M.D.,Ph.D.. The registered enrollment target is 45 participants, below the 179-participant average among 10 other Adult trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05024175, a study of Adult and CAR-T, is actively recruiting participants, sponsored by Marcela V. Maus, M.D.,Ph.D..

RECRUITING
Registry status
45 participants
Enrollment target
1
Study location

Study Summary

This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).

Primary Outcome

defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive

Interventions

  • PROCEDURE Tumor Biopsy
  • DIAGNOSTIC_TEST Disease assessments
  • DIAGNOSTIC_TEST Blood test

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2023-08-07
Est. Completion 2039-08-01
Marcela V. Maus, M.D.,Ph.D.

8 total trials

What NCT05024175 shows while recruiting

NCT05024175 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 179-participant average among 10 other Adult trials with a reported enrollment target (75% lower).

The record links to 7 conditions, with Adult appearing as the primary indexed condition, and to 3 interventions - of which Tumor Biopsy is the first listed.

NCT05024175 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05024175 about?

NCT05024175 is a clinical study titled "Long-term Follow-up of Subjects Treated With CAR T Cells". This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).

What is the current status of trial NCT05024175?

This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2023-08-07. Estimated completion is 2039-08-01.

What conditions does trial NCT05024175 study?

This clinical trial studies the following conditions: Adult, CAR-T, Long Term Adverse Effects, Duty to Follow Up, Progression-Free Survival.

What interventions are being tested in trial NCT05024175?

The interventions under investigation include: Tumor Biopsy (PROCEDURE), Disease assessments (DIAGNOSTIC_TEST), Blood test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05024175?

This trial is sponsored by Marcela V. Maus, M.D.,Ph.D., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05024175 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05024175's enrollment target sits among peer trials

45 7th of 10 higher than 4 of 10 other Adult trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05024175, the US trial registry maintained by the National Library of Medicine. NCT05024175 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.